Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jun 11, 2021 12:44pm
195 Views
Post# 33372822

RE:RE:Good News

RE:RE:Good NewsJohnandrose22 wrote
Shaun Shirazi, PhD..”It is exciting to see Theralase clear another hurdle...and move one step closer to achieving its next milestone of enrolling and treating twenty five patients in early 2021”.

Reading Dr. Shirazi’s words gives me increasing confidence that “early 2021” is understood as the first half of this year, ie the end of this month. I anticipate the company sharing that it has reached its next milestone at the AGM.

John

Yes Johnandrose22, my read on early 2021 is anything prior to the end of June, so I am definitely excited on that statement which to me does refer to a swing to the upside for enrollment/treated patients. This year under CEO DR. Shirazi's leadership has been very impressive and am also looking forward to the AGM.

<< Previous
Bullboard Posts
Next >>